Form 4: Xenon Pharmaceuticals Director Dawn Svoronos Acquires Significant Equity Through Stock Options and RSUs

Xenon Pharmaceuticals Inc. Director Dawn Svoronos has increased her beneficial ownership in the company by acquiring 17,012 stock options and 2,645 restricted share units (RSUs) on June 5, 2025.

Summary

• Dawn Svoronos, a Director of Xenon Pharmaceuticals Inc. (XENE), acquired 17,012 share options and 2,645 Restricted Share Units (RSUs) on June 5, 2025.
• The share options have an exercise price of $30.73 and expire on June 4, 2035.
• Both the share options and RSUs vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Each restricted share unit represents a contingent right to receive one Common Share.
• Following these transactions, Ms. Svoronos beneficially owns 17,012 share options and 2,645 Restricted Share Units directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director's acquisition of equity, particularly through options and RSUs, generally indicates confidence in the company's future and aligns management interests with shareholders. This is a routine compensation event but still a positive signal.

Positives

• The acquisition of additional equity by a director, Dawn Svoronos, signals increased alignment of her interests with those of the shareholders.
• Equity grants are a common form of compensation for directors, incentivizing long-term performance and commitment to the company's success.

Future Outlook

This Form 4 filing primarily reports past transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule of the granted equity.

Industry Context

Equity compensation, including stock options and restricted share units, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors. Such grants align the interests of the board members with the long-term value creation for shareholders, which is particularly crucial in a research-intensive sector like biotech where long development cycles are common.

Comparison to Industry Standards

• The granting of stock options and restricted share units to directors is a common compensation practice in the biotechnology and pharmaceutical sectors, aligning with industry standards for executive and board remuneration.
• The vesting schedule, tied to a future date or the next annual meeting, is typical for such grants, ensuring continued commitment from the director.
• The exercise price of $30.73 for the options reflects the market price at the time of grant, a standard practice for 'at-the-money' options.

Related Party Transactions

• The acquisition of equity by Dawn Svoronos, a Director of Xenon Pharmaceuticals Inc., constitutes a related party transaction as it involves a company insider.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The acquired share options and restricted share units are scheduled to vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Transaction, Stock Options, Restricted Share Units, RSUs, Director Compensation, Equity Grant, Beneficial Ownership